Company: Merck Research Laboratories
Job title: Clinical Director, Sr. Principal Scientist Oncology Clinical Research
Dr. Shih joined MSD Late Stage Oncology in 2018 leads several global phase 3 immunotherapy studies in gastric cancer, notable KN811 (HER2 positive), KN585 (Neoadjuvant/adjuvant), KN-61 and KN63 (both second line), lead protocol development of KN975 (esophageal chemoradiotherapy study), and is global lead for the recently open LEAP-15 (lenvatinib+pembro+chemo) in gastric cancer. Dr. Shih received his MD from George Washington University, residency at Cleveland Clinic Foundation in Pediatrics, and hematology/oncology fellowship at St. Jude Children’s Research Hospital. Prior to joining MSD, Dr. Shih was Associate Professor at Indiana University and Director of the Brain Tumor Program at Riley Hospital for Children. Dr. Shih was the former co-chair for the Plexiform Committee for the NF Clinical Trials Consortium (NFCTC). Prior to MRL, was active PI in several consortiums, including the NFCTC, Children’s Oncology Group (COG), and the NEXT pediatric brain tumor consortium, member of the CNS committee of the COG.
Live Presenter Q&A 1:50 pm
day: Day Two
Investigating the Safety & Efficacy of Pembrolizumab Plus Trastuzumab in Patients With HER2-Positive Gastric Cancer (KEYNOTE 811) 12:10 pm
• Phase 3 trial building on promising Phase 2 data in HER2 positive gastric cancer • Challenges of Global Biomarker selected Clinical trial • Impact/challenges of Practice Preferences/Standards on maintaining homogeneity of trial subjectsRead more
day: Day Two